Biotech Values

[DewDiligence]

New Survey on Biogenerics Legislation

Please refer to #msg-20694180 for a description of the Kennedy-Clinton-Enzi-Hatch bill (“K-C-E-H”), which is currently moving through the U.S. Senate.


Q1: What is your expectation for biogenerics legislation during 2007?

a) No biogenerics bill will be enacted into law during 2007.
b) A bill will be enacted into law in 2007
in substantially the same form as K-C-E-H.
c) A bill will be enacted into law in 2007 that
will be substantially different from K-C-E-H.


Q2 (To be answered only by those who selected answer “c” to Q1 above):
The main distinction between K-C-E-H and the bill to be enacted is:

a) The enacted bill will confer less than 12 years of
marketing exclusivity for branded biologic drugs.
b) The enacted bill will not allow substitutability
of a generic for a branded biologic drug.
c) Some other difference.

--
To vote, please go to
http://www.investorshub.com/boards/board_surveymenu.asp?board_id=1418
and select survey #92.